Est. 2026 — Reward & Motivation Data Layer
Dopaix builds the clinical data layer for companies working at the frontier of dopaminergic medicine — from ADHD treatment analytics to addiction therapy platforms and neuropsychiatric biomarker research.
Dopamine (Greek: dopa = DOPA amino acid) — the molecule of motivation, reward, and drive. The most discussed neurotransmitter of the 21st century.// Core infrastructure
Longitudinal stimulant response tracking, symptom trajectory analysis, and medication optimization data — built for ADHD digital health platforms, telehealth prescribers, and neuropsychiatric clinical trials.
Structured outcomes infrastructure for dopamine-related addiction treatment — from opioid use disorder to behavioral addiction platforms. Session tracking, craving analytics, and long-term recovery monitoring.
Integrate dopamine metabolites, reward sensitivity scores, and neuropsychiatric risk markers into your clinical platform — the data infrastructure for precision psychiatry and behavioral medicine.
// Why now
Dopamine is the defining neurochemical of our era. ADHD, addiction, motivation — all dopamine. The infrastructure isn't there yet.
No neuroscience concept has entered mainstream culture more powerfully than dopamine. From Andrew Huberman's protocols to ADHD awareness movements to addiction medicine — dopamine is the framework through which an entire generation understands motivation, reward, and mental health.
The clinical markets built on dopaminergic science are massive and growing: ADHD telehealth, addiction treatment platforms, neuropsychiatric drug development, behavioral medicine. Every one of them needs the same foundational data infrastructure — and none of it has been purpose-built for dopaminergic medicine specifically.
Dopaix is that infrastructure. Built for the precision psychiatry era, designed around the clinical language of dopaminergic medicine.
// Get in touch
We are selectively onboarding infrastructure partners and early customers. Tell us about your platform and what you are building in dopaminergic or neuropsychiatric medicine.